Global Herceptin Biosimilar Market Insights, Forecast to 2028

Herceptin is the cancer medication used in the treatment of the breast cancer. It is monoclonal antibodies and are used along with the chemotherapy drugs. It is also termed as a targeted therapy drug. Trastuzumab is the one of the brand name herceptin which is administered by slow injection to a vein.
Market Analysis and Insights: Global Herceptin Biosimilar Market
Due to the COVID-19 pandemic, the global Herceptin Biosimilar market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Breast Cancer accounting for % of the Herceptin Biosimilar global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital & Clinics segment is altered to an % CAGR throughout this forecast period.
China Herceptin Biosimilar market size is valued at US$ million in 2021, while the US and Europe Herceptin Biosimilar are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Herceptin Biosimilar landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Herceptin Biosimilar include Amgen, AryoGen Biopharma, Biocon, Celltrion, Gedeon Richter, Genor Biopharma, Mabion, Mylan and Roche and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Herceptin Biosimilar Scope and Segment
Herceptin Biosimilar market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Herceptin Biosimilar market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Breast Cancer
Colorectal Cancer
Leukemia
Lymphoma
Other
Segment by Application
Hospital & Clinics
Oncology Centers
Other
By Company
Amgen
AryoGen Biopharma
Biocon
Celltrion
Gedeon Richter
Genor Biopharma
Mabion
Mylan
Roche
The Instituto Vital Brazil
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E